Cytokinetics Inc (CYTK)
54.70
-1.26
(-2.25%)
USD |
NASDAQ |
Nov 14, 16:00
54.71
+0.01
(+0.02%)
After-Hours: 20:00
Cytokinetics Free Cash Flow (Quarterly): -102.20M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -102.20M |
| June 30, 2024 | -101.23M |
| March 31, 2024 | -129.51M |
| December 31, 2023 | -74.11M |
| September 30, 2023 | -96.42M |
| June 30, 2023 | -122.52M |
| March 31, 2023 | -122.69M |
| December 31, 2022 | -101.40M |
| September 30, 2022 | -90.37M |
| June 30, 2022 | -91.33M |
| March 31, 2022 | -27.75M |
| December 31, 2021 | -62.49M |
| September 30, 2021 | -54.47M |
| June 30, 2021 | -38.29M |
| March 31, 2021 | -36.14M |
| December 31, 2020 | 45.60M |
| September 30, 2020 | 11.78M |
| June 30, 2020 | -28.30M |
| March 31, 2020 | -31.18M |
| December 31, 2019 | -20.36M |
| September 30, 2019 | -21.27M |
| June 30, 2019 | -24.73M |
| March 31, 2019 | -27.16M |
| December 31, 2018 | -12.54M |
| September 30, 2018 | -32.59M |
| Date | Value |
|---|---|
| June 30, 2018 | -26.91M |
| March 31, 2018 | -30.07M |
| December 31, 2017 | -24.85M |
| September 30, 2017 | -25.93M |
| June 30, 2017 | -31.52M |
| March 31, 2017 | -22.33M |
| December 31, 2016 | 76.98M |
| September 30, 2016 | -12.43M |
| June 30, 2016 | -11.23M |
| March 31, 2016 | -17.93M |
| December 31, 2015 | -10.15M |
| September 30, 2015 | -10.40M |
| June 30, 2015 | -9.362M |
| March 31, 2015 | 34.23M |
| December 31, 2014 | -8.377M |
| September 30, 2014 | -9.615M |
| June 30, 2014 | -9.80M |
| March 31, 2014 | -18.16M |
| December 31, 2013 | -12.68M |
| September 30, 2013 | 10.24M |
| June 30, 2013 | 6.58M |
| March 31, 2013 | -12.40M |
| December 31, 2012 | -7.183M |
| September 30, 2012 | -8.924M |
| June 30, 2012 | -8.706M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-129.51M
Minimum
Mar 2024
45.60M
Maximum
Dec 2020
-63.67M
Average
-68.30M
Median
Free Cash Flow (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 39.52M |
| Biomarin Pharmaceutical Inc | 200.30M |
| Catalyst Pharmaceuticals Inc | 72.61M |
| Sarepta Therapeutics Inc | -107.96M |
| Ocugen Inc | -10.42M |